Valvular Heart Diseases Treatment Market
Global Valvular Heart Diseases Market Size, Share & Trends Analysis by Diseases (Aortic Valve Replacement, Heart Valve Disease, Mitral Valve Stenosis, and Others), By Diagnosis (Cardiac Catheterization, Electrocardiogram (ECG), Chest X-Ray, Stress Testing, Others), By Treatment (Medication and Surgery), By End-Users (Hospital & Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast, 2021-2027 Update Available - Forecast 2024-2030
The global valvular heart disease market is growing at a considerable CAGR of around 8.0% during the forecast period. The major factors that drive the market growth include the increasing prevalence of coronary artery diseases, cardiovascular disease, and heart attack, Additionally, the increasing geriatric population diagnosed with heart disease is the risk factor for valvular heart disease. The increasing government initiatives on research and development, approval of minimally invasive surgeries, are anticipated to fuel the global valvular heart disease treatment market. For Instance, In April 2019, Boston Scientific Corporation received approval from the US Food and Drug Administration (FDA) for its transcatheter aortic valve replacement (TAVR) technology LOTUS Edge aortic valve system. The technology is used for the patient with severe aortic stenosis and considered high risk for surgical valve replacement via open-heart surgery. The LOTUS Edge valve system is one of the only FDA-approved aortic valves that provides surgeons with the preference to change the position valve and completely recapture the valve once it has been fully deployed.
However, the high cost of the treatment for valvular heart diseases can harm the global valvular heart disease treatment market. Implantable devices such as annuloplasty rings, heart valves, and grafts are the most acceptable treatment options for valvular heart diseases. Also in the case of mechanical heart prosthetics, patients are in the continuing direction of blood turpentine or anticoagulant drugs which additionally makes the treatment expensive. Also, the high accuracy and patented knowledge required for the development and organization of these devices sustain high costs.
Impact of COVID-19 on the Valvular Heart Diseases Market
The global valvular heart disease market is propelled by the COVID-19 pandemic since December 2019. this market will not face any negative impact. As covid -19 can be more severe to the patients having prior chronic diseases the key players in this market are introducing new products which will aids patients diagnosed with valvular heart diseases.
Segmental Outlook
The market is segmented based on diseases, diagnosis, treatment, and end-user. Based on diseases, the market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, others (tricuspid valve disorders). Based on diagnosis the market is segmented into cardiac catheterization, electrocardiogram (ECG), chest x-ray, stress testing, others). Based on treatment, the market is segmented into medication, surgery. Based on end-user, the market is segmented into hospitals & clinics, ambulatory surgical centers, research institutes.
Global Valvular Heart Diseases Market Share By Disease, 2020 (%)
The aortic valve replacement segment projected to dominate the global Valvular Heart Diseases Market
Based on the diseases, aortic valve replacement is further estimated to dominate the market. The market is primarily driven by the increasing prevalence of heart disease across the globe contributes to the growth of the segment. The growing clinical trials that would lead to the primer of new products in the market certainly contribute to the market growth. The high costs, and growing regulations related to product approvals, would negatively impact the market. Moreover, the increasing geriatric population is also contributing to the increasing prevalence of valvular heart disease treatment due to people over the age of 70 years are susceptible to aortic stenosis. In addition, around 15% of the patients 40 years or above age are likely to suffer from aortic stenosis due to bicuspid aortic valve. Aortic stenosis is the second most common valvular lesion in the US.
Regional Outlooks
The global valvular heart diseases market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global valvular heart disease treatment market. Some factors that are boosting the market growth in North America are the number of cases increases in valvular disorders started increasing North America is the highest contributor of the market. Due to the initiative by the government, and non-government organizations in North America, and reimbursement policies and awareness among the local people also play a vital role in the success of the regional market. Nearly 1.5 million people suffer from aortic stenosis in the US. The presence of the key player in the region, and the increasing number of clinical studies drive the growth of the market in the region.
Global Valvular Heart Diseases Market, by region 2021-2027
Asia-Pacific will have Considerable Growth in the Global Valvular Heart Diseases Market
The Asia-Pacific is projected to witness significant growth opportunities for the market. Due to the increasing incidence of heart diseases in the region, increasing prevalence of heart disease and the rising aging population, and the developing healthcare system, infrastructure, and services. All these factors improvise the growth of this market in this region, Also the government has started funding this type of program and started an awareness program for the benefit of the people.
Market Player Outlook
The major key players in this market are Abbott Laboratories, Becton, Dickinson and Company, Boston Scientific Corp., CryoLife, Inc., Edwards Lifesciences Corp., Medtronic, Plc, Siemens Healthcare Medical Solutions Ltd. These companies are developing various strategies such as mergers & Aqusationsns, Extensive Clinical studies. For Instance, In December 2018, JenaValve Technology received approval from the US Food and Drug Administration for the treatment of patients with severe aortic stenosis and severe aortic regurgitation.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Valvular Heart Diseases market based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Valvular Heart Diseases Industry
• Recovery Scenario of Global Valvular Heart Diseases Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Valvular Heart Diseases Market by Diseases
5.1.1. Aortic Valve Replacement
5.1.2. Heart Valve Disease
5.1.3. Mitral Valve Stenosis
5.1.4. Others (Tricuspid Valve Disorders)
5.2. Global Valvular Heart Diseases Market by Diagnosis
5.2.1. Cardiac Catheterization
5.2.2. Electrocardiogram (ECG)
5.2.3. Chest X-Ray
5.2.4. Stress Testing
5.2.5. Others
5.3. Global Valvular Heart Diseases Market by Treatment
5.3.1. Medication
5.3.2. Surgery
5.3.2.1. Valve Repair
5.3.2.2. Valve Replacement
5.4. Global VALVULAR HEART DISEASES Market by End-Users
5.4.1. Hospital & Clinics
5.4.2. Ambulatory Surgical Centers
5.4.3. Research Institutes
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories
7.2. B. Braun Melsungen AG
7.3. Becton, Dickinson and Co.
7.4. Biotronik SE & Co. KG
7.5. Boston Scientific Corp.
7.6. Braile Biomédica
7.7. Cardiac Dimensions Pty. Ltd.
7.8. CardiaMed
7.9. Cardiosolutions, Inc.
7.10. Cook Group Inc.
7.11. CryoLife, Inc.
7.12. Edwards Lifesciences Corp.
7.13. HLT, Inc.
7.14. JenaValve Technology, Inc.
7.15. Lepu Medical Technology (Beijing) Co., Ltd.
7.16. LivaNova PLC
7.17. Medtronic, PLC
7.18. Micro Interventional Devices, Inc.
7.19. NeoChord, Inc.
7.20. Neovasc Inc.
7.21. ON-X Life Technologies Inc.
7.22. Osypka Medical GmbH
7.23. Siemens Healthcare Medical Solutions Ltd.
7.24. Terumo Corp.
7.25. Toray Industries, Inc.
7.26. TTK Healthcare Ltd.
7.27. Venus Medtech
1. GLOBAL VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
2. GLOBAL VALVULAR HEART DISEASES MARKET BY DISEASES, 2020-2027 ($ MILLION)
3. GLOBAL AORTIC VALVE REPLACEMENT MARKET BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL HEART VALVE DISEASE MARKET BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL MITRAL VALVE STENOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL OTHER HEART VALVE DISEASE MARKET BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL VALVULAR HEART DISEASES MARKET BY DIAGNOSIS, 2020-2027 ($ MILLION)
8. GLOBAL CARDIAC CATHETERIZATION FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL ELECTROCARDIOGRAM (ECG)FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL CHEST X-RAY FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL STRESS TESTING FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL OTHERS VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL VALVULAR HEART DISEASES MARKET BY TREATMENT, 2020-2027 ($ MILLION)
14. GLOBAL MEDICATION VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL SURGERY FOR VALVULAR HEART DISEASES MARKET BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL VALVULAR HEART DISEASES MARKET BY END-USER, 2020-2027 ($ MILLION)
17. GLOBAL VALVULAR HEART DISEASES FOR HOSPITAL & CLINICS MARKET BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL VALVULAR HEART DISEASES FOR AMBULATORY SURGICAL CENTERS MARKET BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL VALVULAR HEART DISEASES FOR RESEARCH INSTITUTES MARKET BY REGION, 2020-2027 ($ MILLION)
20. GLOBAL VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
21. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
22. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
23. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
24. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
25. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
26. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
27. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
28. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
29. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
30. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
31. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
32. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
33. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
34. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
35. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
36. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
37. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
38. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
39. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
40. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL VALVULAR HEART DISEASES MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL VALVULAR HEART DISEASES MARKET BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL VALVULAR HEART DISEASES MARKET, 2021-2027 (%)
4. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY DISEASES, 2020 VS 2027 (%)
5. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
6. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
7. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY END-USER, 2020 VS 2027 (%)
8. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL AORTIC VALVE REPLACEMENT MARKET BY REGION, 2020 VS 2027 (%)
10. GLOBAL HEART VALVE DISEASE MARKET BY REGION, 2020 VS 2027 (%)
11. GLOBAL MITRAL VALVE STENOSIS MARKET BY REGION, 2020 VS 2027 (%)
12. GLOBAL OTHER VALVULAR HEART DISEASES MARKET BY REGION, 2020 VS 2027 (%)
13. GLOBAL CARDIAC CATHETERIZATION FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
14. GLOBAL ELECTROCARDIOGRAM (ECG) FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
15. GLOBAL CHEST X-RAY FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
16. GLOBAL STRESS TESTING FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
17. GLOBAL OTHER FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
18. GLOBAL MEDICATION FOR VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020 VS 2027 (%)
19. GLOBAL SURGERY FOR VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020 VS 2027 (%)
20. GLOBAL VALVULAR HEART DISEASES FOR HOSPITAL & CLINICS MARKET BY REGION, 2020 VS 2027 (%)
21. GLOBAL VALVULAR HEART DISEASES FOR AMBULATORY SURGICAL CENTERS MARKET BY REGION, 2020 VS 2027 (%)
22. GLOBAL VALVULAR HEART DISEASES FOR RESEARCH INSTITUTES MARKET BY REGION, 2020 VS 2027 (%)
23. US VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
24. CANADA MARKET VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
25. UK VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
26. GERMANY VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
27. SPAIN VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
28. FRANCE VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
29. ITALY VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
30. REST OF EUROPE VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
31. INDIA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
32. CHINA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
33. JAPAN VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
34. SOUTH KOREA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF ASIA-PACIFIC VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
36. REST OF WORLD VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
